Cortexyme announces pipeline update and anticipated 2021 milestones

South san francisco, calif.--(business wire)--cortexyme, inc. (nasdaq: crtx), a clinical stage biopharmaceutical company pioneering potential therapeutics for alzheimer's and other degenerative diseases, today announced a corporate update and highlighted key milestones anticipated in 2021. “2020 was a year of numerous corporate and clinical accomplishments. we exceeded our enrollment target in the pivotal gain trial for alzheimer's disease on schedule and completed a successful interim analysis
QNCX Ratings Summary
QNCX Quant Ranking